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Sir,
Tumour necrosis factor α (TNF-α) is a proven adequate 
target for treatment of psoriasis. The chimeric TNF-α 
antibody infliximab binds to the transmembrane recep-
tors and induces a neutralizing effect on soluble TNF by 
reversed signalling, ultimately causing a reduction in 
lesional T cells and, indirectly, increased programmed 
cell death of keratinocytes (1). 
CD26/dipeptidylpeptidase IV (DPPIV) is a multifunc-
tional glycoprotein known to be present and upregulated 
on the surface of keratinocytes and T cells in psoriatic 
skin compared with the skin of healthy volunteers (2). 
The expression of CD26/DPPIV on peripheral blood 
T-lymphocytes of untreated psoriatic patients, however, 
was found to be substantially reduced, in particular on 
the CD8+CD26bright subset (3). Furthermore, TNF-α 
has been reported to influence CD26/DPPIV expression 
(4, 5). In vitro cell cultures have shown that anti-TNF-α 
can upregulate the expression of CD26/DPPIV on 
human-activated lymphocytes (6). 
CD26/DPPIV expression may have a crucial role and 
might function as a marker correlating with disease 
activity in the pathogenesis of psoriasis. The objective 
of this study was therefore to determine whether anti-
TNF-α therapy with infliximab modulates CD26/DPPIV 
expression on keratinocytes and T cells. 
PATIENTS AND METHODS
Eight patients with moderate-to-severe plaque-type psoriasis (defi-
ned as Psoriasis Area and Severity Index (PASI) ≥ 12) participated 
in this 16-week study. At baseline, after 2, 6 and 14 weeks patients 
received an infusion with infliximab 5 mg/kg. Approval of the 
medical ethics committee was obtained and all patients provided 
written informed consent before any study-related procedures 
were performed. Interfering topical or systemic treatments had 
been suspended for at least 2 and 4 weeks, respectively, prior to 
participation, and their use was prohibited throughout the study. 
One solitary plaque of at least 3 cm diameter was chosen as a 
target lesion. In all patients 4-mm punch biopsies were taken at 
weeks 0 (T = 0), 2 (T = 2) and 16 (T = 16) from representative sites 
in the designated target lesion, after anaesthesia with 1% xylocaine/
adrenaline. The obtained specimens were embedded in Tissue-Tek 
OCT compound (Sakura, Zoeterwoude, The Netherlands), snap-
frozen in liquid nitrogen and stored at –80°C until use.
Peripheral blood for enumeration of lymphocytes was obtained 
at the same time-points as the biopsies were collected.
At each visit severity scores (PASI) and sum-score (for the 
severity of the target lesion) were assessed. The sum-score com-
prises the total score for erythema (0–4), induration (0–4) and 
scaling (0–4). 
Immunohistochemical staining was performed on all obtained 
biopsies, as described previously (7). The following primary 
antibodies (mouse anti-human) were used: anti-CD3 1:100 (clone 
UCTH1), anti-CD8 1:200 (clone C8/144B) both from DAKO 
(Copenhagen, Denmark) and anti-CD26 1:50 (clone BA-5) from 
SantaCruz Biotechnology (Santa Cruz, USA). Furthermore, 
haema toxylin and eosin (H&E) staining was performed. 
The immunohistochemical CD26/DPPIV stained sections were 
analysed as described previously (8). The scoring of the epidermal 
CD26/DPPIV expression comprised assessing the honeycomb- and 
column-like patterns of epidermal staining. In addition, the per-
centage of the total keratinocytes positive for CD26/DPPIV was 
estimated along a 5-point scale: 0 = 0%, 1 = 1–29%, 2 = 30–59%, 
3 = 60–89% and 4 = 90–100%.
Quantification of the CD3+ and CD8+ T-cell subsets in the im-
munohistochemically stained sections was carried out as described 
previously (7). Quantitative cell counts of these T-cell subsets were 
expressed as “Positive cells per mm skin length”.
The Zenon labelling technique, as described previously (9), was 
used to combine the aforementioned antibodies. Microscopy and 
image analysis of the sections and antibodies was performed as 
described previously (2). 
The following monoclonal antibodies were used for flow cy-
tometry: CD3-FITC (Beckman Coulter), CD4-PC7 (Beckman 
Coulter), CD8-PECy5 (Beckman Coulter) and CD26-PE (Becton 
Dickinson) (quadruple staining). Aliquots of 100 µl peripheral 
blood were analyzed as previously described (3).
All assays were run on a FC500 flow cytometer (Beckman Coul-
ter, Cytomics FC500). A regional gate was set on CD3+ (FITC) 
vs. forward scatter (FSC) to gate for T lymphocytes in the sample 
being studied. At least 20,000 gated events were acquired for each 
antibody combination.
Statistical analyses were performed using SPSS 14.0 software. 
Analysis of variance with repeated measurement (ANOVA) was 
used to analyse the effect of treatment and time. If significant, 
Bonferroni’s post-hoc comparison was performed to assess time-
related effects. Statistical significance was set at 0.05.
RESULTS
Of 8 enrolled patients, 6 completed the study as 2 drop-
ped out at between 2 and 16 weeks of treatment, both 
due to infusion-related adverse events, and were ex-
cluded from further analysis. The participating patients 
had an age range of 36–55 years and the male:female 
ratio was 3:3. The PASI had decreased significantly af-
ter 2 weeks of therapy, from 19.27 ± 3.17 (mean ± SEM) 
to 12.35 ± 2.45 (p < 0.05). This decrease extended after 
16 weeks of therapy to a mean PASI of 2.52 ± 0.38, 
equivalent to a mean reduction of 86.9% (p < 0.001). 
Equally, the sum-score of the biopsied target lesion 
decreased significantly from baseline to 16 weeks of 
treatment (p < 0.001). In line with this, the thickness of 
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the epidermis narrowed from 266 ± 48 µm at baseline 
to 74 ± 7 µm after 16 weeks (p < 0.001). 
In general, compared with the epidermis, the dermis 
contained larger amounts of CD3+ and CD8+ T cells per 
mm skin length. At week 2, treatment with infliximab 
had induced a significant reduction in the CD3+ T-cell 
subset in the dermis (mean reduction 48.4% (p = 0.009), 
but not yet in the epidermis (mean reduction 36.2%). 
Subsequently, at week 16, mean decreases in the num-
ber of CD3+ T cells in the dermis and epidermis were 
69.6% (p = 0.001) and 83.8% (p = 0.002), respectively. 
With respect to the CD8+ T-cell subset, a significant 
decrease was seen after 16 weeks of treatment in both 
the dermis (p = 0.01) and epidermis (p < 0.01). However, 
this decrease was significant after 2 weeks of therapy 
only in the dermis, not in the epidermis.
Treatment with infliximab did not provoke significant 
alterations in the honeycomb-like pattern of CD26/
DPPIV staining, nor did it influence the percentage of 
CD26/DPPIV positively stained keratinocytes during 
therapy in our patients. 
CD8+ T cells in the psoriatic dermis and epidermis 
expressed CD26+ on their surface, although in small 
amounts (Fig 1; top panel).
The lower panel in Fig. 1 shows that both the double-
labelled CD3CD26 and CD8CD26 T cells in the dermis 
and epidermis tend to decrease under therapy with in-
fliximab (a non-significant difference between baseline, 
2 weeks and 16 weeks of therapy).
No significant changes were observed in the mean 
percentages of CD3+, CD4+ and CD8+ T-cell subsets. 
When focusing on the CD26-negative/dim/bright sub-
populations (7) of the CD3+, CD4+ and CD8+ T cells in 
the present study, no significant alterations in mean per-
centages were found during therapy with infliximab. 
DISCUSSION
In agreement with previous findings, the results of this 
study show that infliximab induces a remarkable clini-
cal effect, together with a reducing effect on lesional T 
cells and thinning of the epidermis. Nevertheless, after 
effective anti-TNF-α therapy, CD26/DPPIV appeared 
to remain present in equal amounts on keratinocytes in 
the epidermis, and on T cells in the peripheral blood. 
In the dermis and epidermis, however, the expression 
of CD26/DPPIV on CD3+ T cells tended to decrease. 
Moreover, the clinical improvement after infliximab 
therapy paralleled the reduction in epidermal thickness 
and of CD3+ and CD8+ T cells in the dermis and epider-
mis. Within the population of double-labelled T cells, 
the CD3CD26- and CD8CD26-positive cells tended 
to decrease after treatment. It is attractive to speculate 
that the hypothesized upregulation of CD26 on T cells 
in response to anti-TNF-α therapy could be evened out 
by a downward effect of the clinical response on the 
T-cell-related expression of CD26/DPPIV. 
The fact that CD26/DPPIV remains present on the 
surface of keratinocytes can be compared to previous 
findings with respect to CD26/DPPIV enzyme activity 
in uninvolved skin of psoriatic patients (8). Both the 
uninvolved skin and the “post-treatment plaque” skin 
after effective treatment in psoriatic patients encompass 
and retain their expression of CD26/DPPIV. The unin-
volved psoriatic skin can be regarded as a subclinical 
psoriatic manifestation. Therefore, CD26/DPPIV may 
play an important role in the initiation or triggering 
of the local immune system in psoriasis. In contrast, 
T-cell-related expression of CD26 tended to reduce 
during infliximab therapy. It is therefore plausible that 
these T cells possess independent functions and patterns 
of expression, which are likely to be separately regulated 
in time and context. This confirms the attributed moon-
lighting character of the CD26 protein (5, 10).
In a previous investigation, it was found that the 
CD8CD26bright subpopulation was reduced (< 10% 
of peripheral CD8+ T cells) in the peripheral blood of 
psoriatic patients compared with healthy volunteers (3). 
The current study shows that the specific CD26 subsets 
of the CD3+, CD4+ and CD8+ peripheral blood T-cell 
Fig. 1. Phenotyping of CD8+CD26+ T cells 
in lesional psoriatic epidermis using the 
Zenon immunofluorescence double-labelling 
technique. (Top panel) Co-staining of CD8 
(green) and CD26 (red) in lesional psoriatic 
skin revealed co-localization of these two 
proteins (merge; yellow) in the epidermis 
(white arrows). (Panel below) Overview of 
mean changes in, respectively, the percentage 
of (epi)dermal double-labelled CD3+CD26+ 
T cells, and the percentage of (epi)dermal 
double-labelled CD8+CD26+ T cells during 
treatment with infliximab. T: time-point in 
weeks; ED: epidermis; D: dermis. Error bars 
indicate standard error of the mean (SEM).
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populations (incorporating the CD26negative, CD26dim 
and CD26bright T cells) were stable over time during 
treatment. These data suggest that significant clinical 
improvement of psoriasis after infliximab therapy does 
not go hand in hand with significant fluctuations in the 
various T-cell populations and CD26-related T-cell 
subsets in peripheral blood. As a result, the CD26bright 
subpopulation of the CD8+ T cells in the peripheral 
blood remained consistently reduced (less than 10%) 
during therapy with infliximab. 
Although the present findings add insight into the ex-
pression of CD26/DPPIV in psoriasis, the small sample 
size defines the pilot character of this study, and larger 
studies are needed to confirm the present observations. 
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